MUNICH, April 23, 2015 /PRNewswire/ --
- Ulrike Verzetnitsch will lead with immediate effect all of apceth's production activities and manufacturing operations.
- Expansion of the capabilities of apceth's global GMP manufacturing business
The cell therapy company apceth GmbH & Co. KG is continuing to expand its senior management team and has announced the appointment of Ulrike Verzetnitsch as Chief Technical Officer with immediate effect.
In this newly created role, Ulrike Verzetnitsch will add considerable value to the company by leading apceth's production facilities and operations and continuing the expansion of its fee-for-service GMP manufacturing business.
Ulrike Verzetnitsch will bring along the broad experience she has gathered in the pharmaceutical sector from her roles in leading pharma and biotech companies. She is joining apceth from her role at Takeda, where she was Head of the Production Unit in Singen, Germany. Before that she held the position of Director of Production with Baxter. There, she focused on strategic tasks in the final container operation of vaccines and plasma-based and recombinant products. As part of her role, she gained professional experience in the manufacturing of products for worldwide distribution in compliance with the US FDA, EMEA, Japanese and other guidelines. She led the development of new production areas for commercial as well as clinical (phase 1 to 3) production, increased output and developed her organization unit.
Ulrike Verzetnitsch has an education in Biochemistry and holds a Master's Degree in Chemical Engineering from the Technical University in Vienna, Austria. She started her career in the pharmaceutical industry in the year 2000.
"apceth has recently started phase II of the world's first clinical trial with genetically modified mesenchymal stem cells in cancer indications and is simultaneously increasing its manufacturing capacity and capabilities as a CMO. It is therefore a very exciting time for us to welcome Ulrike to the team," said Christine Guenther, CEO of apceth. "Her experience will complement our management team and help drive apceth forward."
apceth is a pioneering clinical-stage biopharmaceutical company which is expanding its pipeline of next-generation cell-based therapeutics. Our modular platform technology is based on genetically-modified MSCs, and the lead program Agenmestencel is a first-in-man, genetically-modified MSC for the treatment of cancer. In addition, we are developing new cell therapy candidates for the treatment of lung diseases and inflammation. Based in Munich, we provide our know-how, expertise and GMP-certified facilities to industrial and academic partners around the world.
apceth was founded in 2007 as a start-up company and is privately owned by its founders and private investors, such as Santo GmbH (Andreas and Thomas Strüngmann).
SOURCE apceth GmbH & Co.KG